Free Trial

Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Wall Street Zen to "Buy" Rating

Supernus Pharmaceuticals logo with Medical background

Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Supernus Pharmaceuticals Trading Down 1.7%

NASDAQ:SUPN traded down $0.57 on Friday, reaching $33.39. 350,091 shares of the stock traded hands, compared to its average volume of 487,715. Supernus Pharmaceuticals has a 1-year low of $27.05 and a 1-year high of $40.28. The company's 50 day moving average is $32.26 and its 200-day moving average is $33.73. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of 30.10 and a beta of 0.70.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Large investors have recently modified their holdings of the company. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $30,000. Versant Capital Management Inc grew its position in Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $42,000.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Recommended Stories

Should You Invest $1,000 in Supernus Pharmaceuticals Right Now?

Before you consider Supernus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.

While Supernus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines